ClinicalTrials.gg
RecruitingNCT07359820ReFocus202Updated Nov 9, 2026

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

A Phase 2 interventional study of Lirafugratinib in FGFR2 Gene Fusion/Rearrangement and Other Solid Tumors, Adult, sponsored by Elevar Therapeutics. Recruiting at 19 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Elevar Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 9, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement.

Participants will:

  • Take lirafugratinib regularly as instructed by their study doctor.
  • Visit the clinic as instructed for checkups and tests.
  • Keep a diary recording each time a dose of lirafugratinib is taken.
02

Conditions studied

  • FGFR2 Gene Fusion/Rearrangement
  • Other Solid Tumors, Adult
03

In context

Lead sponsor

Elevar Therapeutics is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unresectable, locally advanced, or solid tumor (other than CCA).
  • Documented FGFR2 gene fusion or rearrangement per local testing of blood and/or tumor.
  • Patient must have per v1.1• Patient has performance status of 0-1.
  • Previously (>30 days) treated with ≥1 including chemotherapy (e.g., gemcitabine/cisplatin), immunotherapy, radiation therapy, or other approved therapies.
  • Subject has not received prior treatment with an FGFRi.

Exclusion criteria

Exclusion Criteria:

  • An uncontrolled comorbidity.
  • Patient does not have adequate organ function (defined in protocol).
  • Patient has active infection, including (HIV), virus (HBV), and/or virus (HCV) (defined in protocol). Patients with well-controlled HBV are eligible (defined in protocol).
  • corrected using Fridericia's formula (QTcF) > 480 msec or history of prolonged QT syndrome, Torsades de pointes or familial history of prolonged QT syndrome.
  • , uncontrolled cardiovascular disease.
  • or primary CNS tumor that is associated with progressive neurologic symptoms.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Lirafugratinib

    Treatment with standard dose of lirafugratinib

    Drug: Lirafugratinib

Interventions

  • DrugLirafugratinib

    Lirafugratinib is an oral inhibitor of FGFR2

    Also known as: RLY-4008

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) assessed by Independent Review Committee per RECIST v1.1.

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months.

Secondary outcomes

  1. Duration of response (DOR) assessed by Independent Review Committee per RECIST v1.1.

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months.

  2. Number of patients with adverse events and serious adverse events.

    Time frame: Every cycle (4-week cycles) until study discontinuation, approximately 24 months.

  3. Number of patients with dose interruptions.

    Time frame: Every 28-day cycle until end of treatment, approximately 24 months.

  4. Number of patients with dose reductions.

    Time frame: Every 28-day cycle until end of treatment, approximately 24 months.

  5. Number of patients with dose discontinuations.

    Time frame: Every 28-day cycle until end of treatment, approximately 24 months.

  6. Objective Response Rate (ORR) as assessed by Investigator per RECIST v1.1.

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months.

  7. Duration of Response (DOR) as assessed by Investigator per RECIST v1.1.

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months

  8. Disease control rate (DCR) as assessed by Investigator and Independent Review Committee per RECIST v1.1.

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months.

  9. Progression-free survival (PFS) as assessed by Investigator and Independent Review Committee per RECIST v1.1.

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months

  10. Overall survival (OS).

    Time frame: Up to approximately 36 months.

  11. Time to response (TTR) assessed by Investigator and Independent Review Committee per RECIST v1.1.

    Time frame: Up to approximately 36 months.

  12. Time to progression (TTP) assessed by Investigator and Independent Review Committee per RECIST v1.1.

    Time frame: Up to approximately 36 months

  13. Pharmacokinetic parameters including maximum plasma drug concentration (Cmax)

    Time frame: [Time Frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through Cycle 4 (4-week cycles)]

  14. Pharmacokinetic parameters including area under the plasma concentration versus time curve (AUC)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through Cycle 4 (4-week cycles)

  15. Pharmacokinetic parameters including half-life (t1/2)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through Cycle 4 (4-week cycles)

  16. Change from baseline in quality of life as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).

    It scores (0-100) where higher means better function/quality of life in that section of the questionnaire and higher means worse symptoms in that section of the questionnaire.

    Time frame: Approximately every 4 weeks during treatment, approximately 24 months

  17. Time to deterioration (TTD).

    Time frame: Up to approximately 36 months.

  18. FGFR2 gene status in plasma circulating tumor deoxyribonucleic acid (ctDNA) and tumor tissue.

    Time frame: Every cycle (4-week cycles) through Cycle 3 and every other cycle thereafter until study discontinuation, approximately 24 months.

  19. Pharmacodynamic parameters including changes in fibroblast growth factor 23 (FGF-23).

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every other cycle (4-week cycles) from Cycle 3, approximately 24 months.

  20. Pharmacodynamic parameters including changes in carcinoembryonic antigen (CEA)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every other cycle (4-week cycles) from Cycle 3, approximately 24 months

  21. Pharmacodynamic parameters including changes in cancer antigen 19-9 (CA 19-9)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every other cycle (4-week cycles) from Cycle 3, approximately 24 months

  22. Correlation between FGFR2 genotype by central tissue assessment and antitumor response, as measured by Objective Response Rate (ORR).

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months.

07

Study locations

14 of 19 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Sep 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 22, 2026
StartActual
Jun 4, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Centre Leon Berard · Lyon, FranceNot yet recruiting→Recruiting
  • Sarah Cannon Research Institute UK · London, United KingdomNot yet recruiting→Recruiting
Nov 9, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Centre Leon Berard · Lyon, FranceContact added c•••@lyon.unicancer.fr · •••2828Contact added (no phone or email listed)
  • Sarah Cannon Research Institute UK · London, United KingdomContact added e•••@sarahcannonresearch.co.uk · •••5200Contact added (no phone or email listed)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Centre Leon Berard · Lyon, FranceNot yet recruiting→Recruiting
    • Sarah Cannon Research Institute UK · London, United KingdomNot yet recruiting→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Centre Leon Berard · Lyon, FranceContact added c•••@lyon.unicancer.fr · •••2828Contact added (no phone or email listed)
    • Sarah Cannon Research Institute UK · London, United KingdomContact added e•••@sarahcannonresearch.co.uk · •••5200Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07359820
Lead sponsor
Elevar Therapeutics
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Jun 4, 2026
Primary completion
Sep 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Elevar Therapeutics
Contact
info-clinicalstudy@elevartx.com
+1 (385) 276-3800

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion